Dade Behring To Distribute Drug Tests Manufactured By Immunalysis
Deerfield, IL - Dade Behring Inc. and Immunalysis announced recently that they have signed an agreement allowing Dade Behring to distribute four prescription medication drug tests manufactured by Immunalysis. The agreement also includes a commitment between Dade Behring and Immunalysis related to working together to meet certain future needs of the dynamic drug-testing market.
This distribution agreement will allow Dade Behring to broaden its portfolio of drug tests by providing customers with tests for oxycodone, tramadol and meperidine--all commonly prescribed pain medications that are also considered drugs of abuse. The agreement also includes a test for buprenorphine, which is used to treat opioid dependence and is increasingly used to replace methadone for treating heroin addiction.
"The misuse of therapeutic drugs is rapidly growing and becoming a global health care concern," said Jim Reid-Anderson, Chairman, President and CEO, Dade Behring. "As the global leader in drugs-of-abuse testing for more than thirty years, expanding our portfolio to include new therapeutic drug tests is important to us. This agreement will allow our customers to benefit from a broader drug-testing portfolio and help them to better meet their facilities' needs," concluded Reid-Anderson.
Dade Behring is a global market leader in drug testing and celebrated its 40th anniversary of the Syva drug testing product line in 2006. Under the Syva brand name, Dade Behring offers a wide variety of tests that either detect or provide quantitative measures of therapeutic drugs, drugs-of-abuse, and drugs used to prevent rejection of transplanted organs. In addition to hospital and reference clinical laboratories, the Company serves criminal justice and occupational health laboratories, among others.
SOURCE: Dade Behring